Below are current clinical trials.4 studies in Chronic kidney disease
(open studies only).
Filter this list of studies by location, status and more.
The purpose of the ISCHEMIA-CKD trial is to determine the best management strategy for patients with stable ischemic heart disease (SIHD), at least moderate ischemia and advanced chronic kidney disease (CKD; estimated glomerular filtration rate [eGFR] <30 or on dialysis). This is a multicenter randomized controlled trial with a target randomization of ~1000 patients with advanced CKD and at least moderate ischemia on stress testing. Participants will be assigned at random to a routine invasive strategy (INV) with cardiac catheterization (cath) followed by revascularization plus optimal medical therapy (OMT) or to a conservative strategy (CON) of OMT, with cath and revascularization reserved for those who fail OMT. The trial is designed to run seamlessly in parallel to the main ISCHEMIA trial as a companion ancillary trial. SPECIFIC AIMS A. Primary Aim. The primary aim of the ISCHEMIA-CKD trial is to determine whether an invasive strategy of routine early catheterization followed by optimal revascularization, in addition to OMT, will reduce the primary composite endpoint of death or nonfatal myocardial infarction in SIHD patients with advanced CKD and at least moderate ischemia over an average follow-up of approximately 4 years compared with an initial conservative strategy of OMT alone with catheterization reserved for those who fail OMT. The primary endpoint is time to centrally adjudicated death or nonfatal myocardial infarction (MI). B. Secondary Aims. Major: To compare angina-related quality of life between the INV and CON strategies. Other secondary aims include: comparing the incidence of the composite of cardiovascular death, nonfatal myocardial infarction, resuscitated cardiac arrest, or hospitalization for unstable angina or heart failure; composite of cardiovascular death or nonfatal myocardial infarction; cardiovascular death; non-fatal myocardial infarction; all-cause death; stroke; hospitalization for heart failure or unstable angina Condition: Coronary Disease Procedure: Cardiac catheterization Phase: Phase III Condition: Cardiovascular Diseases Procedure: Angioplasty, Transluminal, Percutaneous Coronary, other catheter-based interventions Phase: Phase III Condition: Heart Diseases Procedure: Coronary Artery Bypass Surgery Phase: Phase III
The purpose of this study is to develop educational materials that will help patients and clinicians talk about treatment options for patients with advanced kidney disease.
The purpose of this study of obinutuzumab administered as intravenous (IV) infusion in adults with end stage renal disease is to assess the safety and tolerability of the regimen at week 24 of the desensitization phase and at week 28 post kidney transplantation. All participants will be monitored for a minimum of 12 months following the last obinutuzumab infusion.
To determine the effect of 12 weeks of chronic PDEV inhibition with Tadalafil versus placebo on basal cardiorenal and humoral function and on the integrated cardiorenal and humoral response to acute sodium loading in subjects with preclinical systolic dysfunction (PSD) and renal (kidney) dysfunction.
Aug. 09, 2016
- Goldman L, et al., eds. Chronic kidney disease. In: Goldman-Cecil Medicine. 25th ed. Philadelphia, Pa.: Saunders Elsevier; 2016. http://www.clinicalkey.com. Accessed April 21, 2016.
- Ferri FF. Chronic kidney disease. In: Ferri's Clinical Advisor 2016. Philadelphia, Pa.: Mosby Elsevier; 2016. https://www.clinicalkey.com. Accessed April 21, 2016.
- AskMayoExpert. Chronic kidney disease (adult). Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2015.
- Bope ET, et al. The urogenital tract. In: Conn's Current Therapy 2016. Philadelphia, Pa.: Elsevier; 2016. http://www.clinicalkey.com. Accessed May 3, 2016.
- About chronic kidney disease: A guide for patients and their families. National Kidney Foundation. http://www.kidney.org/atoz/content/aboutckd.cfm. Accessed May 3, 2016.
- Rosenberg M. Overview of the management of chronic kidney disease in adults. http://www.uptodate.com/home. Accessed April 21, 2016.
- Coping effectively: A guide for patients and their families. The National Kidney Foundation. https://www.kidney.org/atoz/content/coping_effectively_guide. Accessed May 3, 2016.
- Chronic kidney disease: What does it mean for me? National Institute of Diabetes and Digestive and Kidney Diseases. http://www.niddk.nih.gov/health-information/health-communication-programs/nkdep/a-z/kidney-disease-mean-for-me/Pages/default.aspx. Accessed April 28, 2016.
- Chronic kidney disease (CKD) and diet: Assessment, management and treatment. National Kidney Disease Education Program. http://www.niddk.nih.gov/health-information/health-communication-programs/nkdep/a-z/Documents/ckd-diet-assess-manage-treat-508.pdf. Accessed April 28, 2016.
- Kidney failure: Choosing a treatment that's right for you. National Institute of Diabetes and Digestive and Kidney Diseases. http://www.niddk.nih.gov/health-information/health-topics/kidney-disease/kidney-failure-choosing-a-treatment-thats-right-for-you/Pages/facts.aspx. Accessed May 3, 2016.
- Cook AJ. Allscripts EPSi. Mayo Clinic, Rochester, Minn. Feb. 23, 2016.
- Heilman RL (expert opinion). Mayo Clinic, Phoenix, Ariz. May 12, 2016.